CDK4 and breast cancer: Data from DepMap, where ER+ breast cancer cell lines underwent systematic gene silencing to identify genes essential for survival [42], show that CDK4 knockout yields much lower DepMap CRISPR CERES scores than CDK6 knockout [43], indicating stronger dependency on CDK4 than CDK6 for viability.